Lidbree

Lidocaine, the active ingredient in Lidbree, is a local anesthetic presented as a sterile solution for intracervical and intrauterine use. By blocking nerve conduction, it delivers rapid, localized numbness, facilitating gynecologic and obstetric interventions while minimizing patient discomfort.

GNH USA supplies Lidbree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable global distribution. The product complies with EU regulatory requirements and is available for bulk procurement through established logistics networks.

Lidocaine is a local anesthetic used to achieve targeted nerve block in the cervical and uterine tissues. - Cervical anesthesia for gynecologic procedures: provides localized numbness to facilitate interventions such as cervical biopsies and loop electrosurgical excision. - Intrauterine anesthesia for obstetric interventions: reduces pain during procedures like uterine curettage, hysteroscopy, and embryo transfer. - Pain control during hysteroscopic surgery: enables patient comfort while allowing precise operative manipulation.

Lidbree may cause a range of adverse reactions following intracervical or intrauterine administration.

Common Side Effects: - Burning or stinging at the injection site - Redness or mild swelling of the treated area - Dizziness or light‑headedness - Nausea or mild vomiting

Serious or Rare Side Effects: - Cardiovascular collapse, arrhythmias, or severe hypotension - Central nervous system toxicity such as seizures or loss of consciousness - Severe allergic reactions including anaphylaxis

Prior to using Lidbree, clinicians should assess patient history and monitor for potential complications. - Allergy assessment: verify no known hypersensitivity to lidocaine or other amide‑type anesthetics. - Cardiac evaluation: consider baseline ECG in patients with known heart disease. - Dosage calculation: ensure dose is appropriate for the intended procedure and patient weight. - Monitoring: observe vital signs during and after administration for signs of toxicity. - Store below 25°C: keep in the original container, protect from moisture and direct light.

Lidbree can interact with other medications that affect cardiac conduction or drug metabolism.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may increase lidocaine toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise plasma lidocaine levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers and calcium channel blockers: may enhance cardiac depressant effects. - Diuretics: can alter plasma concentration of lidocaine. - General anesthetics: may potentiate central nervous system depression.